Among different cancer types, HER2 overexpression and amplification are more prevalent than point mutations, particularly in breast, gastric, colorectal cancers, and non-small cell lung cancer (NSCLC), where specific anti-HER2 targeted therapies have been approved [28,29]. This evidence concerns the gene ERBB2 and cancer.